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This study was carried out to further elucidate the effects
of adenosine and adenosine-5'-triphosphate (ATP) on
atrioventricular (AV) conduction in patients. Adenosine
(0.24 mg/kg) and ATP (0.28 mg/kg) were administered
intravenously to 37 patients undergoing intracardiac
electrophysiologic evaluation. Both adenosine and ATP
depressed AV conduction by lengthening the atrial to
His bundle (AH) interval. The effects of adenosine and
ATP after rapid intravenous bolus administration were
fast in onset (15 ± 0.5 and 15 ± 1.5 s, respectively),
but transient in duration (10.5 ± 0.5 s for ATP and
17 ± 3 s for adenosine). Although muscarinic blockade
with 0.04 mg/kg atropine shortened the AH interval from
a control value of 123 ± 12 to 74 ± 4 ms, it did not
modify the effects of adenosine or ATP, or both (that
is, latency and duration of the effects were not signifi-
cantly different from before atropine administration).
Adenosine and related compounds (for example, adenosine-
5'-triphosphate [ATP]) are known to depress impulse con-
duction through the atrioventricular (AV) node in various
species including human subjects (1-14). The AV block
caused by adenosine and ATP is caused by a prolongation
of the atrial to His bundle (AH) interval without any de-
monstrable effect on His to ventricle (HV) conduction time
(5,7,8). In addition, current evidence (15) indicates that the
effects of adenosine on the AV node are mediated by an
extracellular receptor that is competitively antagonized by
aminophylline but not by atropine.
ATP seems to have a negative dromotropic action similar
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In contrast, aminophylline, a competitive antagonist
of adenosine, completely prevented the effects of aden-
osine and ATP. Aminophylline alone also shortened the
AH interval from a control value of 98 ± 9 to 74 ± 9
ms.This decrease was blocked by propranolol (0.1 mg/kg),
whereas propranolol did not influence the ability of ami-
nophylline to antagonize the effects of adenosine or ATP.
or both. Thus, the cateeholamines released by amino-
phylline are unlikely to account for the ability of ami-
nophylline to antagonize the effects of adenosine and
ATP.
In conclusion, these findings indicate that intrave-
nously administered adenosine and ATP are equally ef-
fective in producing AV block that is antagonized by
aminophylline but not by atropine.
(J Am Coil CardioI1985;5:1212-9)
to that of adenosine, and in recent years both agents have
gained important clinical significance (10--14). Because ATP
can be rapidly degraded to adenosine diphosphate (ADP),
with ADP degraded to adenosine monophosphate (AMP)
and AMP dephosphorylated to adenosine, it is conceivable
that some of the ATP effects on the AV node are mediated
by adenosine. However, in some species, such as the dog
and cat, atropine or vagotomy partially antagonize the
chronotropic and dromotropic effects of ATP (16-19). Thus,
depending on the species, the dromotropic effects of ATP
could be due to its degradation to adenosine or to vagal
activation with release of acetylcholine, or a combination
of both.
Since in more recent studies both ATP and adenosine
have been proposed to be useful therapeutic methods for
the termination of reentrant supraventricular arrhythmias
involving the AV node, in our study we sought to investigate
and compare the effects of ATP and adenosine in human
subjects. Specifically, we examined the dromotropic effects
of ATP and adenosine and whether their response could be
modified by atropine or aminophylline, or both.
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Methods
Patients. Thirty-seven patients (22 men and 15 women)
with a mean age (± SO) of 42.6 ± 9.6 years were subjected
to the research protocol outlined later and to electrophysi-
ologic studies after written informed consent had been ob-
tained. These patients were selected from a series of 290
electrophysiologic studies during a period of 18 months.
Pertinent clinical features and admission diagnoses of these
patients are listed in Table 1.
None of the patients studied had structural heart disease.
Table 1. Summary of 37 Patients
In addition, before entering the study, all patients were
investigated electrophysiologically for assessment of AV
nodal function (with atrial and ventricular stimulation at
increasing frequencies) and for induction of arrhythmias
(with atrial and ventricular programmable stimulation). Only
those patients with no demonstrable disturbance of impulse
formation and conduction (that is, 37 of 290 patients) en-
tered the study. Furthermore, at the time of the study, all
cardioactive agents had been withheld for at least 48 hours
before the investigation. Patients undergoing treatment with
agents known to interfere with adenosine metabolism (for
Group
A
B
C
D
E
Patient Age Admission
No. Sex (yr) Diagnosis
I M 57 Dizz, S Brad
2 M 40 Syn
3 F 43 Syn
4 F 29 Palp, Short PR
5 M 35 Dizz, Palp, S Brad
6 F 40 Dizz, PVC
7 M 39 Palp, Short PR
8 M 25 PSVT
9 M 37 Dizz, S Brad
10 F 42 Dizz, S Brad
II M 43 Palp, Short PR
12 F 43 Sync
13 F 52 Dizz, S Brad
14 M 57 Palp, Short PR
15 M 28 Dizz, S Brad
16 F 31 Palp, Short PR
17 M 53 Palp, Dizz
18 M 50 Sync
19 F 41 Dizz, VT
20 M 37 Palp, PVC
21 F 36 Palp, Short PR
22 M 47 Dizz, Palp, Short PR
23 M 42 PSVT, R Pre-Ex
24 M 52 PSVT, R Pre-Ex
25 M 27 Syn
26 F 31 Palp, PVC
27 F 52 Dizz, VT
28 M 55 Dizz, PVC
29 M 35 Dizz, S Brad
30 M 50 Palp, Short PR
31 M 60 Syn
32 F 43 Dizz, PVC
33 F 36 Palp
34 F 42 Dizz
35 M 50 Palp, Short PR
36 M 60 Dizz
37 F 36 PSVT
Dizz = dizziness; F = female; M = male; Palp = palpitation; PSVT = paroxysmal supraventricular
tachycardia; PVC = premature ventricular complex; R Pre-Ex = retrograde pre-excitation; S Brad = sinus
bradycardia; Syn = syncope; VT = ventricular tachycardia.
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example, dipyridamole or diazepam) were excluded from
the study .
Electrophysiologic studies. Three (two bipolar and one
quadripolar) 6F USCI electrode catheters with a 10 mm
interelectrode distance were inserted percutaneously through
the femoral veins. One catheter was positioned across the
AV junction for recording the His bundle potential, another
was placed in the right ventricle apex and a thir~ quadripolar
catheter was positioned along the lateral wall of the right
atrium in such a way that the proximal electrodes recorded
the high right atrial electrocardiogram (HRA), whereas the
distal electrodes were used for atrial stimulation. The in-
tracardiac e1ectrograms and scalar electrocardiographic leads
i, III and VI were displayed On a multichannel oscilloscope
(HP4568C) and simultaneously recorded on photographic
paper (paper speed 100 mrn/s) of a Hewlett Packard recorder
(model HP4368C). Cardiac stimulation was performed with
a programmable stimulator (Bloom Associates) set to deliver
rectangular wave pulses of2 ms duration and twice threshold
intensity .
Adenosine, adenosine-S ' -triphosphate (ATP) as well as
the other drugs (such as ATP [Ormonoterapia Richter , It-
aly], atropine sulfate (Monico, Italy], propranolol [Inderal ,
IC Pharma Italy] and aminophylline [Recordari, Italy]) were
administered intravenously througp it Cournand catheter po-
sitioned at the level of the superior vena c~va and right
atrium . Adenosine (Sigma Chemical COIppany) was dis-
solved in normal saline solution. The adenos ine solution
was prepared under sterile conditions', and its purity as de-
termined by high pressure liquid chromotography was 9,7%;
therefore, the contamination with inosine and hypoxanthine
was 3%:
Protocol. The 37 patients were classified into five groups
(Groups A, B, C, D and E).
Group A (n = 20). In this group of patients, we tested
whether atropine could alter the effects of ATP. Two rapid
intravenous bolus injections of ATP (0.28 mg/kg) were ad-
ministered. A control injection was followed by a second
injection performed 3 minutes after intravenous administra-
tion of 0 .04 mg/kg of atropine sulfate . Throughout the ex-
perimental period, the atrial rate was maintained at-a fre-
quency of 130 beats/min.
Group B (n = 4). In this group of patients, we examined
whether aminophylline modifies the response to ATP in-
jections. A control intravenous injection of ATP (0.28 mglkg)
was followed by administration of aminophylline (5 mg/kg),
Aminophylline was given intravenously during a 5 minute
period. The second injection of ATP (at the same dose as
the first) was performed 3 minutes after the administration
of aminophylline. As in the case of Group A, the atrial rate
was kept at 130 beats/min . :
Group C (n = 4). This group differs from Group B in
that the patients were pretreated with propranolol. Initially,
propranolol (0.1 mg/kg) was administered intravenously
during a 7 minute period. The first bolus injection of ATP
(0.28 mg/kg) was given 5 minutes after the administration
of propranolol. Ten minutes later, 5 mg/kg of aminophylline
was administered (during a 5 minute period) intravenously .
The second bolus injection of ATP was given 3 minutes
after aminophylline administration. In this group of patients ,
the atrial rate was maintained at 100 beats/min.
Group D (n = 5) . In this group , we investigated whether
atropine could alter the response to adenosine injections.
Similar to Group A, two rapid intravenous bolus injection s
of adenosine (0 .24 mg/kg) were administered. A control
injection was followed by a second injection performed 3
minutes after intravenous administration of 0.04 rug/kg of
atropine sulfate. Atrial pacing at 130 beats/min was main-
tained throughout the experiment.
Group E (n = 4). In this group of patients, we inves-
tigated whether aminophylline could modify the effects of
adenosine. All patients in this group were pretreated (that
is, beforethe injection of adenosine) with propranolol (0 . 1
mg/kg) administered intravenously during a 7 minute pe-
riod. A cQntrol injection of adenosine (0.24 mg/kg) was
given 5 minutes after the administration of propranolol. Ten
minutes later, 'intravenous aminophylline (5 mg/kg during
a 5 minute period) was given. Th~ second bolus injection
of adenosine (0.24 mg/kg) was given 3 minutes after ami-
nophylline administration. Atrial rate was maintained at 100
beats/min.
Results
Adenosine-5' -triphosphate (ATP) (Group 1\). In this
group of 20 patients, during atrial pacing at a constant rate
(130 'beats/min), the control AH and HV intervals were
125 ± 7 and 37 ± 1 ms, respectively. ATP at a dose of
0.28 ± 0.05 rug/kg (mean ± 1 SD) produced second and
third degree AV block in 6 and 14 patients, respectively.
In all patients, the ATP-induced AV block was preceded
by an abrupt prolongation of the AH interval, whereas the
HV interval remained unchanged. The AV block caused by
ATP was rapid in onset and transient (Fig. I). figure 2 (left
panel) summarizes the characteristics (latency and duration)
of the AV. block produced by ATP; the time to onset (la-
tency) of AV block after rapid bolus injection of ATP was
15 ± 0.5 and lasted 10:5 ± 0 .5 s.
Adenosine (Group D). Similar to ATP, intravenous in-
jection of adenosine produced AV block . In this group of
five patients , during atrial pacing at a constant rate (130
beats/min), the control AH and HV intervals were 122 ±
16 and 35 ± 2 ms, respectively . Adenosine at a dose of
0.24 ± 0.04 mg/kg (mean ± I SD) caused second and
third degree AV block in three and two patients, respec-
tively . Like ATP, the adenosine-induced AV block was
preceded by an abrupt and .rapid prolongation of the AH
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Figure 2. Summary of the data comparing the effects of atropine
and aminophylline (AMINO) on the ATP- and adenosine-induced
second degree atrioventricular (AV) block. The mean ± SEM of
the latency and duration of the AV block in seconds are indicated
by the open and closed bars, respectively. All patients who re-
ceived aminophylline were first pretreated with propranolol (*).
Letency AV Bleck
Adenosine
Letency AV Bleck
ATP
*AMINO 1:1 AV Conduction
CONTROL1---
ATROPINEf----
the same as those measured before treatment with atropine
(Fig. 2, left panel). Likewise, the AV block caused by
adenosine was not modified by atropine; that is, latency was
the same (15 ± 1.5 s) and duration of effect, although
slightly shorter (14 ± 2 versus 17 ± 3 s before atropine),
was not significantly different from the control value.
Effect of aminophylline on ATP- and adenosine-in-
duced AV block (Groups B, C and E). Like atropine,
intravenous administration of aminophylline (5 mg/kg)
shortens the AH interval. In this study (Fig. 4B), amino-
phylline significantly shortened the AH interval from a con-
trol value of 98 ± 9 to 74 ± 9 rns, with no change in the
HV interval (not shown in figure). In contrast, propranolol
significantly prolonged the AH interval by 24 ± 8 ms. After
Figure 1. Patient 1 (Group A). Productionof seconddegree atrio-
ventricular (AV) block by adenosine-S'-triphosphate (ATP). The
tracings represent surface electrocardiographic leads III and VI,
His bundle (HBE) and high right atrial (HRA)electrograms. Trac-
ing A is the control state. Tracings Band C are records obtained
at 14 and 25 s, respectively, after intravenous injection of ATP.
The asterisk indicates beats where AV block occurred. Atrial
pacing at a cycle length of 475 ms was maintained throughout the
observation period. A, H and V = atrial, His bundle and ven-
tricular depolarization, respectively; C.L. = cycle length in mil-
liseconds; S = stimulus artifact.
interval, but with no change in the HV interval (Fig. 3).
The time to onset of the AV block caused by adenosine
averaged 15 ± I. 5 s and lasted 17 ± 3 s (Fig. 2, right
panel). The time to onset of the effects of adenosine did
not significantly differ from that of ATP, whereas the du-
ration of the AV block caused by adenosine was significantly
(p < 0.05) longer than that produced by ATP.
Lack of effect of atropine on ATP· and adenosine-
induced AV block. Intravenous administration of 0.04 mglkg
of atropine caused a significant shortening of the AV interval
(Fig. 4A). Control AH and HV intervals were 123 ± 12
and 36 ± 2 ms (mean ± SEM of 25 patients), respectively.
After administration of atropine, the AH interval was sig-
nificantly (p < 0.05) reduced to 74 ± 4 ms, whereas the
HV interval remained unchanged at 36 ± 2 ms. This dose
of atropine, however, did not significantly alter the effect
of ATP or adenosine (Fig. 2). That is, the characteristics
(latency and duration) of the AV block caused by ATP and
adenosine were not modified by atropine. For example, in
the 20 Group A patients, after atropine treatment, the latency
and duration of AV block caused by ATP were 14.5 ± 0.5
and to ± 0.5 s, respectively. These values are essentially
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pretreatment with propranolol, the same dose of amino-
phylline no longer shortened the AH interval. In this group
of patients in the presence of propranolol, the AH interval
was 122 ± 13 ms and after aminophylline administration,
although the AH interval decreased to 116 ± 12 ms (Fig.
4B), this was not considered significant (p < 0.05). In
comparison with atropine, aminophylline antagonized the
ATP- and adenosine-induced AV block whether or not the
patients were treated with propranolol (Fig. 2, 5 and 6). In
addition, aminophylline not only antagonized the AV block
caused by ATP and adenosine, but also prevented the AH
prolongation. In patients treated with aminophylline, the
maximal AH prolongation observed after injection of either
ATP or adenosine was 5 to 10 ms (Fig. 6).
Adverse reactions. All 37 patients reported a mild brief
episode of dyspnea associated with "chest oppression." In
addition, 15 (41%) of the 37 patients experienced facial
flushing. However, none of these side effects were persist-
ent, that is, they lasted only a few seconds and were de-
scribed as of minor intensity. No side effects were noted
after administrationof propranolol, aminophyllineor atropine.
Figure 3. Patient 33 (Group D). Production of second degree AV
block by adenosine during atrial pacing at a cycle length of 465
ms. Tracing A is the control state. Tracings Band C are records
obtained at 14 and 21 s, respectively, after intravenous injection
of adenosine. The asterisk indicates beats where AV block oc-
curred. Abbreviations as in Figure I.
on the HV interval; 2) after rapid bolus administration, their
effects are fast in onset (approximately 10 s), but are tran-
sient, lasting 10 to 20 s; 3) atropine neither prevented nor
altered the time of onset and duration of the AV block; and
4) aminophylline, a competitive antagonist of adenosine,
antagonized their action.
Figure 4. Effect of atropine, aminophylline (AMINO) and pro-
pranolol (PROP) on the atrial to His bundle (AH) conduction time.
The depicted data are the mean values ± SEM for the number of
patients indicated (numbers inside the bars). The AH interval
values were measured during atrial pacing at 130 beats/min for
the atropine and aminophylline groups, and during pacing at 100
beats/min for the propranolol alone or plus aminophylline groups,
or both. The asterisk indicates values significantly different (p <
0.05) from the control state.
Discussion 160 A. 160 B.140 140
*
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Figure 5. Patient 25 (Group C). Inhibition of the adenosine-5'-
triphosphate (ATP) effectson atrioventricular (AV)conduction by
aminophylline administration during atrial pacingat a cycle length
of 640 ms. Tracing A is the control state obtained after pretreat-
ment with propranolol and aminophylline. Note the long AH in-
tervalcomparedwith the AH intervalbeforepropranolol treatment
(Fig. 1 control trace). Tracings Band C were obtained 15 and
25 s, respectively, after injection of ATP. Abbreviations as in
Figure 1.
The effect of both adenosine and ATP on the AH interval
resembles the action of slow channel blocking agents, such
as verapamil and manganese chloride (20). Although in a
previous study (21) it was suggested that the AH prolon-
gation and AV block caused by adenosine are associated
with inhibition of the "slow" calcium-sodium-mediated ac-
tion potentials in the AV node (that is, N zone), its precise
site and mechanism of action have yet to be elucidated. The
rapid onset and transient duration of the adenosine- and
ATP-induced AV block are also similar to the effects of
acetylcholine on the AV node (5,22). However, atropine
antagonizes the effects of acetylcholine but not the action
of adenosine and ATP, except in some species as indicated
below. The transient duration of the effects of adenosine
can be explained by its rapid rate of metabolism, that is,
uptake (by blood and endothelial cells) and deamination to
inosine or metabolism to AMP. In a recent study (23), it
was shown that the half-life of adenosine in undiluted human
blood is less than to s (mean 9.3). This short half-life can
explain the short duration of the adenosine and ATP effects,
as well as why the effect of these compounds greatly de-
pends on how fast they are administered.
Degradation of ATP. In regard to the effects of ATP,
one should note that ATP is rapidly hydrolyzed to AMP,
Figure 6. Patient 36 (Group E). Atten-
uation of the adenosine effects on atrio-
ventricular (AV) conduction by amino-
phylline administration during atrial pacing
at a cycle length of 605 ms. Intravenous
aminophylline was administered after
pretreatment with propranolol. Tracing
A is the control state (that is, after pro-
pranolol and aminophylline). Note that
the control AH interval is longer than the
control interval in Figure 3. Tracings B
and C were obtained at 20 and 38 s, re-
spectively, after intravenous injection of
adenosine.
. . .
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which in tum is dephosphorylated to adenosine. Thus, its
effect may depend on its degradation to adenosine. How-
ever, in some species such as the dog and cat, the effect of
ATP appears, at least in part, to be vagally mediated since
atropine or vagotomy, or both, significantly attenuates its
action (16-19). In contrast, as shown in our study and
previous studies, in human beings both the effects of aden-
osine and ATP at doses known to produce AV block or
terminate supraventricular tachycardia are not antagonized
by atropine (14,24,25). These observations are consistent
with the findings (26) that in the isolated perfused guinea
pig heart, a great part if not all of the AV conduction delay
and block caused by ATP can be attributed to its degradative
product, adenosine. It is interesting to note that in the guinea
pig heart in situ equimolar doses of ATP, ADP, AMP and
adenosine cause a period of AV block with similar latency
and duration, whereas in an isolated perfused guinea pig
heart, adenosine causes a more pronounced impairment of
AV conduction than does ATP (26,27). Similarly, adeno-
sine is twice as potent as ATP in slowing the heart rate in
an isolated guinea pig heart (26). Furthermore, this latter
study showed that ATP was completely dephosphorylated
to adenosine before uptake, and that breakdown of ATP to
adenosine precedes its pharmacologic action. It is conceiv-
able that the reason adenosine and adenine nucleotides are
equipotent in the in situ guinea pig heart (that is, perfused
blood), whereas in the isolated perfused heart with physi-
ologic salt solution adenosine is more potent, is because the
enzymatic dephosphorylation of the nucleotides is probably
greater and faster in blood than in salt solution (26). On the
basis of these observations and our own results, it appears
that the guinea pig is a better experimental model than the
dog or cat for studying the effects of adenosine and its
phosphorylated derivatives on the AV node if the results
are to be extrapolated to human subjects.
Antagonism by aminophylline. Methylxanthines, such
as theophylline, are known to be competitive antagonists of
adenosine (15,28). But methylxanthines also can inhibit
phosphodiesterase, which in tum causes an increase in cyclic
AMP and can release catecholamines from adrenergic nerve
terminals and adrenal medulla (29-32). In our study, admin-
istration of aminophylline caused a significant decrease in
AH interval, which was prevented by propranolol. This
finding suggests that the AH shortening caused by amino-
phylline was likely a result of catecholamines released by
the methylxanthine. In a recent report, Lechat et al. (25)
showed that aminophylline in a dose-dependent manner an-
tagonized the AV block caused by ATP in human subjects.
However, because aminophylline was administered without
prior treatment with propranolol, the possibility remains that
part of the antagonism could have been caused by the cate-
cholamines released. The AV node transmission is sensitive
to sympathetic tone and catecholamines, which explains the
significant prolongation of AH interval after administration
of propranolol (33,34), Since the ability of aminophylline
in reversing the adenosine- and ATP-induced prolongation
of AH and AV block was not affected by propranolol admin-
istration, the catecholamines released by aminophylline are
unlikely to account for our results. Thus, as previously
demonstrated in laboratory animals (15,35), this antagonism
of adenosine and probably ATP effects by aminophylline
is due to blockade of adenosine receptors. Our study, to
our knowledge, is the first to show that in the presence of
propranolol, aminophylline antagonizes the negative drom-
otropic action of adenosine and ATP in human subjects and
that propranolol does not modify (potentiate) the effect of
adenosine and ATP.
Conclusions. In recent years, it has been hypothesized
that adenosine released endogenously by ischemic or hy-
poxic cells, or both, mediates some of the bradyarrhythmias
associated with clinical episodes of impaired blood supply
to the SA and AV nodes (35,36). Consistent with such a
hypothesis are the previous findings in human subjects (14)
that the sinus and AV nodes are sensitive to adenosine and
our results that aminophylline antagonizes the electrophys-
iologic effects of adenosine.
Our study has shown that intravenously administered
adenosine and ATP have a similar potency in depressing
AV nodal conduction, and that this depressed AV nodal
conduction is antagonized by aminophylline but not by atro-
pine. Thus, it is possible that in human beings, as in the
case of the guinea pig and dog, adenosine may play an
important role as a mediator of the bradyarrhythmias ac-
companying myocardial ischemia and hypoxia. Further-
more, our data support the rationale for the use of adenosine
and ATP in the acute management of supraventricular tach-
ycardias involving the AV node. The data also predict that
adenosine and ATP would fail to terminate episodes of
supraventricular tachycardia in patients medicated with
methylxanthines (for example, theophylline) or whose diet
contains high doses of xanthine derivatives such as caffeine.
We thank Richard Crampton, MD, FACC for reviewing the manuscript.
We also acknowledge the assistance of Holly Spicer for helping prepare
the manuscript.
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